e-learning
resources
ERJ
2003
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Dexamethasone treatment does not inhibit fibroproliferation in chronic lung disease of prematurity
Dik W.A., Versnel M.A., Naber B.A., Janssen D.J., van Kaam A.H., Zimmermann L.J.I.
Source:
Eur Respir J 2003; 21: 842-847
Journal Issue:
May
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Dik W.A., Versnel M.A., Naber B.A., Janssen D.J., van Kaam A.H., Zimmermann L.J.I.. Dexamethasone treatment does not inhibit fibroproliferation in chronic lung disease of prematurity. Eur Respir J 2003; 21: 842-847
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Epidermal growth factor in the lungs of infants developing chronic lung disease
Source: Eur Respir J 2001; 18: 796-800
Year: 2001
Decrease of vascular endothelial growth factor in macrophages from long-term smokers
Source: Eur Respir J 2005; 25: 626-633
Year: 2005
Insulin-like growth factor-1 in idiopathic pulmonary fibrosis bronchoalveolar lavage fluid protects lung fibroblasts from apoptosis
Source: Eur Respir J 2001; 18: Suppl. 33, 358s
Year: 2001
Cytokines in chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 50S-59S
Year: 2001
Increased vascular endothelial growth factor in acute eosinophilic pneumonia
Source: Eur Respir J 2003; 21: 774-778
Year: 2003
Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF)
Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease
Year: 2009
Upregulation of basic fibroblast growth factor in smokers with chronic bronchitis
Source: Eur Respir J 2006; 27: 957-963
Year: 2006
HGF and IL-6 in BAL fluid of interstitial lung diseases: effect on human lung fibroblasts
Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease
Year: 2008
Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease
Source: Eur Respir J 2006 Oct 01;28(4):824-831
Year: 2006
Studies on hepatocyte growth factor (HGF) in bronchoalveolar lavage (BAL) do not support the concept on its antifibrotic properties in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
An indicative role of serum transforming growth factor-beta 1 (TGF-β1) level on the determination of clinical severity of pulmonary tuberculosis
Source: Annual Congress 2005 - Diagnosis of tuberculosis and LTBI
Year: 2005
Antifibrotic role of hepatocyte growth factor (HGF) in fibrosing interstial lung diseases
Source: Eur Respir J 2001; 18: Suppl. 33, 367s
Year: 2001
Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Regulation of vascular endothelial growth factor expression in a mouse model of acute respiratory distress syndrome (ARDS)
Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation
Year: 2013
Angiogenetic profiles (VEGF and VEGF receptor-1, Flt-1) in bronchoalveolar lavage fluid in patients with interstitial lung diseases
Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease
Year: 2008
Apoptotic cell instillation after bleomycin attenuates lung injury through hepatocyte growth factor induction
Source: Eur Respir J 2012; 40: 424-435
Year: 2012
Down regulation of human insulin-like growth factor in lung tissue of patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2007; 30: Suppl. 51, 574s
Year: 2007
Hypoxia inducible factor-1? in human emphysema lung tissue
Source: Eur Respir J 2011; 37: 775-783
Year: 2011
Keratinocyte growth factor improves alterations of lung permeability and bronchial epithelium in allergic rats
Source: Eur Respir J 2007; 30: 31-39
Year: 2007
The contribution of transforming growth factor-β and epidermal growth factor signalling to airway remodelling in chronic asthma
Source: Eur Respir J 2006; 27: 208-229
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept